Macrolide antibiotics Market, By drug type (Azithromycin, erythromycin, telithromycin, calirithromycin and fidaxomycin), By Infection (legionella sp., mycoplasma pneumonia, peliosishepatis, bordetella pertussis and others), By Route of administration (oral and parenteral),By End-user, hospital, clinics, ambulatory center, research center and others), and By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Market Trends, Analysis, and Forecast till 2030

Antibiotics originating from Saccharopolyspora erythraea are known as macrolide antibiotics. Macrolide antibiotics have a wide range of action against many gram-positive bacteria and are bacteriostatic in nature. Soft tissue infections, respiratory infections, sexually transmitted infections, and atypical mycobacterial infections are all treated with macrolide antibiotics. Macrolide antibiotics have anti-inflammatory and immunomodulatory properties and are used to treat a variety of ailments. Macrolide antibiotics can be used as a first- or second-line therapy, depending on the situation. Erythromycin is used as a second-line treatment for allergies and is used as a first-line treatment for pertussis and other disorders. The global Macrolide antibiotics market accounted for US$ 39.7 billion in 2020 and is estimated to be US$ 118.1 billion by 2030 and is anticipated to register a CAGR of 11.5%.

Impact of Covid-19 pandemic on market

The COVID-19 virus outbreak, which began in December 2019, has spread to almost every country on the planet, prompting the World Health Organization to declare it a public health emergency. The global effects of the coronavirus disease 2019 (COVID-19) are already being felt, and the Macrolide Antibiotics market will be significantly impacted. COVID-19 has the potential to have three major effects on the global economy: directly influencing production and demand, causing supply chain and consumer instability, and having a financial impact on businesses and financial markets.

Rising initiatives by government bodies

The growth and expansion of the antibiotics market would, in turn, boost the market for macrolide antibiotics. The demand for macrolide antibiotics will continue to increase as the incidence of bacterial skin infections rises. Government policies and regulations that favor macrolide antibiotics would produce even more lucrative growth opportunities.

Growth in business operations by emerging and small sized players

The global demand for Macrolide Antibiotics is expected to expand in the coming years, owing to the rise in antibiotic adoption. The global macrolide antibiotics market is expected to develop rapidly during the forecast period, owing to rising macrolide demand around the world. The market is also expected to rise due to the rising prevalence of bacterial skin infections and the growing number of dermatology clinics. Furthermore, the macrolide drug market is being driven by a growing elderly population, an unprecedented rate of multi-strain resistant bacterial strains, and better benefits over traditional antibiotics.

Source: Prophecy Market Insights |Disclaimer: Data is only a representation. Actual data may vary in the final report.

Source: Prophecy Market Insights

The global Macrolide antibiotics market is segmented based on drug type, Infection, route of distribution, end-user and region.

On the basis of drug type, the global Macrolide antibiotics market is segmented into Azithromycin, erythromycin, telithromycin, calirithromycin and fidaxomycin. Based on Infection, the target market is segmented into Legionella, Mycoplasma, Peliosishepatis, bordetella pertussis and others. On the basis of route of administration, the target market is segmented into oral and parenteral. On the basis of end-user, the market is segmented into hospital, clinics, ambulatory centers and research laboratories.

Regional Insights:

On region the global Macrolide antibiotics market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. Because of the involvement of leading producers and cutting-edge healthcare facilities, North America is the industry leader in Macrolide Antibiotics. Their high investment in Macrolide Antibiotics R&D centers provides a complementing opportunity for the expected market value. South Asia and East Asia have supportive factors in their healthcare platforms that are expected to drive Macrolide Antibiotics market growth over the forecast period.

Report Scope:

Segments Covered in the Report:

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2019 to 2030. For the purpose of this study, has segmented the global Macrolide antibiotics market report based on drug type, Infection, route of distribution, end-user, and region.

Global Macrolide antibiotics Market, By Region:

• • • North America
      • • U.S.
        • Canada
    • Europe
      • • Germany
        • UK
        • France
        • Russia
        • Italy
        • Rest of Europe
    • Asia Pacific
      • • China
        • India
        • Japan
        • South Korea
        • Rest of Asia Pacific
    • Latin America
      • • Brazil
        • Mexico
        • Rest of Latin America
    • Middle East & Africa
      • • GCC
        • Israel
        • South Africa
        • Rest of Middle East & Africa

The key players operating in the global Macrolide antibiotics market includes AbbVie Inc., Allergan, AstraZeneca, Merck & Co., Inc., GlaxoSmithKline plc., Johnson & Johnson Services, Inc., Pfizer Inc., F. Hoffmann-La Roche Ltd, Novartis AG, Eli Lilly And Company., Bristol-Myers Squibb Company, Teva Pharmaceutical Industries Ltd., Novartis AG, Boehringer Ingelheim International Gmbh, Sanofi, Astrazeneca, Abbott, Bayer AG, Sandoz International GmbH and others.

• AbbVie Inc.
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies

• Allergan
• AstraZeneca
• Merck & Co., Inc.
• GlaxoSmithKline plc.
• Johnson & Johnson Services, Inc.
• Pfizer Inc.
• F. Hoffmann-La Roche Ltd
• Novartis AG
•  Eli Lilly And Company.
• Bristol-Myers Squibb Company
• Teva Pharmaceutical Industries Ltd.
•  Boehringer Ingelheim International Gmbh
• Others

“*” marked represents similar segmentation in other categories in the respective section